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The Importance of Hemodynamics*Howard J. Eisen, MDC ardiac transplantation remains the mostdurable therapy for patients with AmericanCollege of Cardiology Foundation/American
Heart Association stage D advanced heart failure
who have exhausted other options, and it is the ther-
apy associated with the best long-term outcomes.
One of the major causes of morbidity and mortality
beyond the ﬁrst year after transplant is cardiac
allograft vasculopathy (CAV), the diffuse transplant
coronary artery disease unique to cardiac transplant
recipients (1–3). Although survival after cardiac trans-
plantation has improved over the past 30 years, this
improvement primarily reﬂects improvements in
patient management within the ﬁrst year after trans-
plant as a result of improved treatment and preven-
tion of rejection and infections. Survival conditional
to 1 year post-transplant has not changed in the
past 30 years (1). CAV is observed in adult and pediat-
ric patients, but the clinical characteristics, the pre-
dictors of clinical outcomes, and the role of the
recent International Society of Heart and Lung Trans-
plantation (ISHLT) grading system nomenclature for
the severity of CAV for the prognostication of out-
comes in pediatric patients have not been well
deﬁned (4).SEE PAGE 547Earlier reports of the clinical predictors of poor
outcomes in pediatric cardiac transplant recipients
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tric patients, were, with a single exception, small,
single-center studies and preceded the publication of
the more recent ISHLT CAV guidelines and nomen-
clature. Therefore, the interpretation of these studies
and their applicability to pediatric cardiac transplant
recipients are generally unclear (5,6). Kindel et al. (7),
participating in the Pediatric Heart Transplant Study,
were able to use the data from this large registry of
pediatric cardiac transplant recipients to better deﬁne
the incidence of CAV, its development over time, and
the incidence of the degrees of CAV severity, which
could now be deﬁned angiographically using the
ISHLT CAV grading system. These investigators were
also able to incorporate hemodynamic measures as a
reﬂection of the restrictive hemodynamics associated
with CAV and as part of the ISHLT deﬁnition of CAV
and its severity. In this analysis of 8,122 angiograms
from 3,120 pediatric cardiac transplant recipients
from 35 U.S. and Canadian centers and 1 British cen-
ter, the conditional incidence of CAV rose from 5% at
2 years post-transplant to 15% at 5 years and 28% at
10 years post-transplant. Of those patients with dis-
ease, 77% had CAV-1 (mild disease), 17% had CAV-2
(moderate disease), and only 6% had CAV-3 (severe
disease). These results indicate that CAV is less
frequent and less severe in pediatric heart transplant
recipients than in adults, an observation made in
other, smaller studies. What sets the study by Kindel
et al. apart from the others and makes it a deﬁnitive
analysis of CAV in pediatric heart transplant re-
cipients is the very large number of patients studied
from multiple centers and the up to 15 years of
angiographic and clinical follow-up, providing a more
complete picture of the time course of development,
frequency of disease, and severity of disease in this
patient population. Of particular interest is the
application of left ventricular (LV) function deﬁned
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559by LV ejection fraction (LVEF) and hemodynamic
data, speciﬁcally right atrial pressure (RAP) and pul-
monary capillary wedge pressure (PCWP) from this
large patient cohort to the determination of clinical
outcomes in patients with speciﬁc severities of CAV.
This approach is logical and accomplishes the func-
tional upgrades noted in the ISHLT CAV nomencla-
ture (which is both angiographic and functional)
and deﬁned as LV systolic dysfunction with an
LVEF <45% or evidence of restrictive hemodynamics,
or both, or a cardiac index <2.1 l/min/m2. As markers
of restrictive hemodynamics, the investigators used
an RAP >12 mm Hg or a PCWP >15 mm Hg. Although
less elevated and less severe than hemodynamic
cutoffs in other studies of pediatric patients, the
deﬁnition of restrictive hemodynamics made using
these values was robust in discriminating patients
with worse outcomes, and these markers served as
surrogates of the microvascular CAV that likely causes
these restrictive hemodynamic features (8–10).
Although patients with CAV had much more
favorable outcomes statistically than did those with
CAV-2 or CAV-3, the addition of RAP, PCWP, and
LVEF allowed the identiﬁcation of patients with
CAV-1 who had graft systolic dysfunction, restrictive
hemodynamics, or both, and who had worse clinical
outcomes, speciﬁcally graft loss, than did patients
with CAV-1 and normal graft function and hemody-
namics. Graft dysfunction, deﬁned as an LVEF <45%,
identiﬁed a population with a greater likelihood of
graft loss regardless of angiographic evidence of CAV,
thus adding credence and validity to this parameter
as a predictor of post-transplant outcomes. Interest-
ingly, more severe LV dysfunction with greater re-
ductions in LVEF did not portend worse outcomes
than did the presence of an LVEF <45%. This ﬁnding
suggests that it is the reduction in LVEF as a result of
CAV that causes worse outcomes and not the extent
of LV dysfunction, thereby differentiating CAV from
graft dysfunction in patients who are not transplant
recipients in whom the extent of LV dysfunction
has implications for survival. Patients with CAV-1 or
CAV-2 and a single functional abnormality, such as
elevated RAP or PCWP above the threshold deﬁned in
this study and described earlier, had signiﬁcantly
worse graft survival than did patients with CAV-1 and
no functional abnormalities. Similarly, patients
with CAV-1 and any functional abnormality, deﬁned
as reduced LVEF <45% or RAP >12 mm Hg or
PCWP >15 mm Hg, had signiﬁcantly worse graft sur-
vival than did patients with CAV-1 without any
functional abnormalities (i.e., normal left ventricular
function and normal right- and left-sided ﬁlling
pressures).The implications of these ﬁndings are several. One
is that the extent of CAV angiographically, albeit
important, cannot be used alone to identify patients
with CAV and increased risk of graft loss; hemody-
namic considerations reﬂecting the presence of
restrictive hemodynamics and graft systolic dys-
function must also be taken into consideration. The
extent of systolic dysfunction does not have to be
severe but could be called “borderline” in patients
who were not heart transplant recipients. In pediatric
transplant recipients, an LVEF <45% should trigger
concern. Moreover, the absence of functional abnor-
malities in patients with CAV-1 and CAV-2 may
slightly mitigate these patients’ outcomes. These
outcomes are still poor, however, conﬁrming the
importance of CAV severity in determining outcome.
Finally, the study by Kindel et al. (7) provides vali-
dation of the ISHLT angiographic and functional
nomenclature as a way of stratifying patients with
CAV in terms of angiographic severity of CAV with or
without functional derangement of the graft (also a
manifestation of CAV) into those at greater risk of
graft loss and reduced survival. From the work of
Kindel et al., it appears that the ISHLT CAV nomen-
clature allows identiﬁcation of pediatric patients with
poor outcomes from CAV. Two single-center studies
found that this is also true in adult cardiac transplant
recipients, a ﬁnding that is not surprising (11,12).
There are limitations with this study, most of
which the investigators addressed. These include
the retrospective nature of the study, which analyzes
a registry. This approach appears to be the only
way that angiographic and functional data from
such a large patient cohort could be obtained and
analyzed. However, almost 42% of patients had
no hemodynamic data at the time of their angio-
grams. Further, echocardiographic hemodynamic
data, which are a part of the ISHLT CAV nomencla-
ture, were not included in the Pediatric Heart Trans-
plant Study database and could not be analyzed; this
is an important deﬁcit. Concomitant causes of graft
dysfunction, such as acute cellular or antibody-
mediated rejection, could not be included in the
analysis, so the role of these factors in functional
abnormalities and outcomes is unknown. The period
of data collection was 1993 to 2009, during which time
immunosuppression regimens changed those using
cyclosporine and azathioprine as a basis to the more
potent tacrolimus-based and mycophenolate mofetil–
based regimens; however, these inﬂuences could not
be assessed through this database, nor could the use
of mTOR (mammalian target of rapamycin) inhibitors
to try to ameliorate the progression of CAV. Addi-
tionally, the effect of changes in immunosuppressive
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560regimens or the use of medications for heart failure,
such as beta blockers, renin-angiotensin-aldosterone
antagonists, and diuretic agents, in response to
functional abnormalities could not be evaluated.
Despite these limitations, the investigators have
provided a clearer view of the incidence, progression,
and severity of CAV in children, as well as validation
of the ISHLT CAV nomenclature stratiﬁcation of
severity of CAV by using the angiographic extent of
CAV and functional abnormalities to identify pediat-
ric cardiac transplant recipients at high risk of graft
loss and poor survival. These investigators modiﬁedthe functional abnormalities to be considered and
relied on lower RAP and PCWP cutoffs to identify
high-risk patients. The question whether these
angiographic and functional abnormalities should
trigger repeat transplantation or changes in immu-
nosuppression could not be answered.
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